Integral Diagnostics Ltd (ASX: IDX) Share Price and News
Price
$2.15
Movement
0.00 (0.0)
as at 5 Mar - Closed (20 mins delayed)
52 Week Range
$1.91 - $3.20
1 Year Return
-6.11%
Integral Diagnostics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
$2.15
Day Change
0.00 (0.0)
52 Week Range
$1.91 - $3.20
Yesterday's Close
$2.15
Today's Open
–
Days Range
– - –
Volume
0
Avg. Volume (1 month)
2,538,858
Turnover
$0
as at 5 Mar - Closed
Should you invest $1,000 in Integral Diagnostics right now?
Before you buy Integral Diagnostics shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys...
See The 5 Stocks *Returns as of 7 February 2025
Integral Diagnostics Ltd (ASX: IDX)
Latest News

Earnings Results
This ASX healthcare stock is crashing 30% on half year results

Small Cap Shares
3 ASX small-cap shares with a 'solid growth outlook' for 2025

Broker Notes
6 ASX All Ords shares lifted to 'strong buy' consensus ratings for the new year

Broker Notes
Here's the latest broker upgrades on ASX All Ords shares

Healthcare Shares
3 small-cap ASX healthcare shares 'with strong prospects'

Earnings Results
Two up, one down: ASX healthcare stocks split after FY24 results

Premium Reports
ASX Reporting Season: The Importance Of The 'Equity' In Equities [PREMIUM CONTENT]

Share Gainers
Why Capitol Health, Infratil, Newmont, and Race Oncology shares are charging higher

Broker Notes
Buy 'em now! Brokers name 3 ASX All Ords shares to add to your portfolio

Share Fallers
Why Bapcor, Chalice Mining, Integral Diagnostics, and Winsome Resources shares are dropping

Share Gainers
Why Capitol Health, Capricorn Metals, Credit Clear, and Telix shares are storming higher

Healthcare Shares
This ASX All Ords stock is rocketing 20% after accepting a takeover offer
Frequently Asked Questions
-
Yes, Integral Diagnostics historically pays two fully franked dividends a year.
-
Integral Diagnostics generally pays its shareholder dividends in April and October.
-
Integral Diagnostics Ltd listed on the ASX on 21 October 2015.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
30 Aug 2024 | $0.0330 | 100.00% | Final | 03 Oct 2024 |
29 Feb 2024 | $0.0250 | 100.00% | Interim | 02 Apr 2024 |
31 Aug 2023 | $0.0350 | 100.00% | Final | 04 Oct 2023 |
02 Mar 2023 | $0.0250 | 100.00% | Interim | 04 Apr 2023 |
01 Sep 2022 | $0.0300 | 100.00% | Final | 05 Oct 2022 |
01 Mar 2022 | $0.0400 | 100.00% | Interim | 04 Apr 2022 |
02 Sep 2021 | $0.0700 | 100.00% | Final | 06 Oct 2021 |
01 Mar 2021 | $0.0550 | 100.00% | Interim | 06 Apr 2021 |
28 Aug 2020 | $0.0400 | 100.00% | Final | 01 Oct 2020 |
28 Feb 2020 | $0.0550 | 100.00% | Interim | 07 Apr 2020 |
30 Aug 2019 | $0.0500 | 100.00% | Final | 02 Oct 2019 |
01 Mar 2019 | $0.0500 | 100.00% | Interim | 02 Apr 2019 |
31 Aug 2018 | $0.0400 | 100.00% | Final | 04 Oct 2018 |
31 Jan 2018 | $0.0400 | 100.00% | Interim | 05 Mar 2018 |
31 Aug 2017 | $0.0000 | 100.00% | Final | 04 Oct 2017 |
28 Feb 2017 | $0.0300 | 100.00% | Interim | 30 Mar 2017 |
31 Aug 2016 | $0.0400 | 100.00% | Final | 04 Oct 2016 |
IDX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
28th Feb 2025 2025-02-28T16:19:39 | Becoming a substantial holder from CGF | YesNo | 4:19pm | 7 | 327k |
27th Feb 2025 2025-02-27T17:08:22 | Update - Dividend/Distribution - IDX | YesNo | 5:08pm | 5 | 18k |
26th Feb 2025 2025-02-26T08:58:18 | Dividend/Distribution - IDX | YesNo | 8:58am | 5 | 18k |
26th Feb 2025 2025-02-26T08:34:58 | FY25 Half Year Results Investor Presentation | YesNo | 8:34am | 28 | 2.5M |
26th Feb 2025 2025-02-26T08:16:33 | FY25 Half Year Results Media Release | YesNo | 8:16am | 5 | 224k |
26th Feb 2025 2025-02-26T08:12:38 | FY25 Half Year Results App4D and Interim Report | YesNo | 8:12am | 32 | 14M |
5th Feb 2025 2025-02-05T11:47:14 | Initial Director's Interest Notice - Dr Mittal | YesNo | 11:47am | 2 | 175k |
5th Feb 2025 2025-02-05T11:46:19 | Appointment of Radiologist Executive Director | YesNo | 11:46am | 1 | 489k |
21st Jan 2025 2025-01-21T14:13:58 | IDX FY25 Half Year Results Release Date and Conference Call | YesNo | 2:13pm | 1 | 367k |
20th Jan 2025 2025-01-20T11:13:36 | Changes to Company Secretary roles | YesNo | 11:13am | 1 | 349k |
About Integral Diagnostics Ltd
Integral Diagnostics Ltd (ASX: IDX) is an Australian healthcare services company providing medical imaging services.
The group operates in a single business providing diagnostic imaging to general practitioners, medical specialists, and allied health professionals and their patients.
The company operates more than 90 radiology clinics across Australia and New Zealand. It is also a joint venture partner in Medx, expanding its services to the United Kingdom and Ireland.
IDX Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
03 Mar 2025 | $2.15 | $0.02 | 0.94% | 2,265,404 | $2.09 | $2.22 | $2.06 |
28 Feb 2025 | $2.13 | $-0.23 | -9.75% | 6,186,920 | $2.30 | $2.34 | $2.13 |
27 Feb 2025 | $2.36 | $-0.15 | -5.98% | 6,025,710 | $2.45 | $2.50 | $2.26 |
26 Feb 2025 | $2.51 | $-0.35 | -12.24% | 20,274,684 | $2.25 | $2.54 | $1.91 |
25 Feb 2025 | $2.86 | $-0.03 | -1.04% | 1,032,502 | $2.88 | $2.88 | $2.83 |
24 Feb 2025 | $2.89 | $0.00 | 0.00% | 1,378,165 | $2.86 | $2.89 | $2.81 |
21 Feb 2025 | $2.89 | $-0.06 | -2.03% | 581,109 | $2.93 | $2.96 | $2.89 |
20 Feb 2025 | $2.95 | $-0.04 | -1.34% | 1,167,913 | $2.99 | $3.02 | $2.92 |
19 Feb 2025 | $2.99 | $0.02 | 0.67% | 686,821 | $2.97 | $3.04 | $2.94 |
18 Feb 2025 | $2.97 | $-0.07 | -2.30% | 447,968 | $3.04 | $3.06 | $2.96 |
17 Feb 2025 | $3.04 | $-0.03 | -0.98% | 1,411,758 | $3.07 | $3.10 | $3.03 |
14 Feb 2025 | $3.07 | $0.10 | 3.37% | 1,081,282 | $2.98 | $3.08 | $2.97 |
13 Feb 2025 | $2.97 | $0.05 | 1.71% | 1,334,144 | $2.95 | $3.04 | $2.94 |
12 Feb 2025 | $2.92 | $-0.02 | -0.68% | 555,700 | $2.92 | $2.95 | $2.90 |
11 Feb 2025 | $2.94 | $-0.01 | -0.34% | 700,355 | $2.96 | $2.96 | $2.92 |
10 Feb 2025 | $2.95 | $-0.02 | -0.67% | 1,431,594 | $2.98 | $2.99 | $2.95 |
07 Feb 2025 | $2.97 | $-0.04 | -1.33% | 239,050 | $3.05 | $3.05 | $2.96 |
06 Feb 2025 | $3.01 | $-0.02 | -0.66% | 883,868 | $3.03 | $3.05 | $3.00 |
05 Feb 2025 | $3.03 | $-0.01 | -0.33% | 913,759 | $3.05 | $3.05 | $2.99 |
04 Feb 2025 | $3.04 | $0.05 | 1.67% | 566,410 | $3.06 | $3.07 | $3.00 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
07 Nov 2024 | James Hall | Buy | 1,833 | $5,425 |
On-market trade.
|
01 Nov 2024 | Ian Kadish | Issued | 327,566 | $979,422 |
Issue of securities. 1,004,570 Rights
|
16 Sep 2024 | Ian Kadish | Issued | 29,072 | $74,424 |
Issue of securities. 677,004 Rights
|
30 Aug 2024 | Ian Kadish | Issued | 26,035 | $67,691 |
Conversion of securities.
|
30 Aug 2024 | Ian Kadish | Exercise | 26,035 | $67,691 |
Conversion of securities. 647,932 Rights,
|
27 Aug 2024 | Ian Kadish | Expiry | 184,616 | $480,001 |
As advised by the company. Lapsed, 673,967 Rights
|
02 Apr 2024 | James Hall | Issued | 1,719 | $3,748 |
Dividend Reinvestment Plan (DRP). As per announcement on 04-04-2024
|
02 Apr 2024 | James Hall | Issued | 1,719 | $3,748 |
Dividend Reinvestment Plan (DRP).
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Andrew James Fay | Non-Executive Director | Jul 2022 |
Mr Fay brings to the Board over 30 years of experience in funds and investment management, including Chief Executive Officer and Chief Investment Officer roles at Deutsche Asset Management Limited. He also held several other senior investment roles at Deutsche Asset Management and previously at AMP Capital. From 1998 to 2006, he was a member of the Investment Board Committee of the Financial Services Council. Andrew is an experienced company director across ASX listed, private and regulated entities and accordingly brings to the Board skills in financial and risk management, capital markets, executive remuneration frameworks, strategy, investment, and corporate governance. He is also Chair of the People and Culture Committee.
|
Ms Raelene Margaret Murphy | Non-Executive Director | Oct 2017 |
Ms Murphy has over 30 years of experience in strategic, financial, and operational leadership in both industry and professional advisory, after beginning her career in audit. She was formerly a Partner in a national accounting firm, Managing Director of Korda Mentha and CEO of the Delta Group. In her professional advisory career, she specialized in operational and financial restructuring, with a particular emphasis on merger and acquisition integration across a range of public and private companies. Raelene is a Fellow of Chartered Accountants Australia and New Zealand and has extensive experience as Chair of Audit and Risk Committees for ASX listed companies. She is Member of the Risk, Compliance and Sustainability Committee and a Member of the People and Culture Committee.
|
Ms Ingrid Anne Player | Non-Executive Director | Aug 2023 |
Ms Player has more than 20 years of experience in the healthcare industry, gained from leadership roles across the private, public and not for profit sectors. In her executive career, Ms Player was Group Executive Legal, Governance and Sustainability at Healthscope, one of Australia's largest private healthcare providers. As a qualified lawyer, she previously worked in private legal practice in Australia and Europe specializing in corporate law, M&A and capital markets. She brings to the Board experience in leveraging corporate transactions and major capital projects to achieve strategic outcomes, as well as skills in risk management, government relations, sustainability and corporate governance. She is Chair of the Risk, Compliance and Sustainability Committee and a Member of the People and Culture Committee.
|
Mr James Tobias Hall | Non-Executive Director | Sep 2023 |
Mr Hall has experience in Australia and New Zealand and is an experienced Board and Committee Chair. Mr Hall was Group CEO of St Vincents Health Australia from 2014 to 2022, He has also overseen multisite, for-profit generating businesses at both board and executive levels in employment services, early learning services and aged care. His experience in M&A includes the acquisition of ABC Childcare from administration. Mr Hall is currently non-executive Chair of Sana Health Group, non-executive Chair of For Purpose Aged Care, non-executive Director of UNICEF Australia, a trustee of Yajilarra and advisory board member for Fujitsu Australia and New Zealand. He is a Member of the Risk, Compliance and Sustainability Committee and a Member of the People and Culture Committee.
|
Dr Ian Kadish | Chief Executive OfficerManaging Director | May 2017 |
Mr Kadish began his career as a medical doctor in Johannesburg, South Africa. Ian was helpful in growing the group from five hospitals with a market capitalisation of $60m, to 119 hospitals and a market capitalisation of $3bn. Since migrating to Australia in 2006, Dr Kadish's roles have included CEO and MD of Healthcare Australia, CEO and MD of Pulse Health Group and CEO of Laverty Pathology. He is also a Director of the Australian Diagnostic Imaging Association (ADIA). He is also Member of the Integral Clinical Leadership Committee. He is a Member of the Integral Clinical Leadership Committee.
|
Ms Laura Nicole McBain | Non-Executive Director | Dec 2024 |
Ms McBain has executive and leadership experience having held roles as Managing Director at Bellamys Australia, Maggie Beer Holdings and Lark Distilling.
|
Dr Kevin (Kai-Chung) Shaw | Non-Executive Director | Dec 2024 |
Dr Shaw is the Director of Medical Imaging at University Hospital Geelong.
|
Mr Manish Mittal | Non-Executive Director | Feb 2025 |
--
|
Mr John J Merity | Company Secretary | Jun 2024 |
-
|
Craig White | Chief Financial Officer |
-
|
|
John J Merity | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Citicorp Nominees Limited | 42,793,666 | 18.29% |
J P Morgan Nominees Australia Pty Limited | 39,158,798 | 16.74% |
HSBC Custody Nominees (Australia) Limited | 38,626,662 | 16.51% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 4,678,603 | 2.00% |
Warbont Nominees Pty Ltd (Unpaid Entrepot A/c) | 4,119,561 | 1.76% |
Washington H Soul Pattinson And Company Limited | 4,087,223 | 1.75% |
HSBC Custody Nominees (Australia) Limited (NT COMNWLTH Super Corp A/C) | 3,906,185 | 1.67% |
Citicorp Nominees Pty Limited (Colonial First State Inv A/C) | 3,552,881 | 1.52% |
BNP Paribas Nominees Pty Ltd (Hub24 Custodial Serv Ltd) | 3,407,901 | 1.46% |
New Imaging Pty Ltd (New Imaging A/c) | 3,389,045 | 1.45% |
Lethean Holdings Pty Ltd (Howitt No 8 A/c) | 2,944,760 | 1.26% |
Firbar Pty Ltd (The Howitt No 4 A/c) | 2,357,230 | 1.01% |
J A Mullins Pty Ltd (James A Mullins Family A/c) | 2,316,051 | 0.99% |
Masfen Securities Limited | 2,250,000 | 0.96% |
Mittal Holdings Pty Ltd (Howitt No 12 A/c) | 2,085,907 | 0.89% |
Mr Vincent Michael O'Sullivan (O'Sullivan A/c) | 2,020,000 | 0.86% |
Wyndham Salter Pty Ltd (The Howitt No 10 A/c) | 1,792,947 | 0.77% |
A & S French Pty Ltd (The AJ French Family A/c) | 1,778,327 | 0.76% |
BNP Paribas Nominees Pty Ltd (Agency Lending A/C) | 1,711,682 | 0.72% |
BNP Paribas Noms Pty Ltd | 1,636,566 | 0.70% |